Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: "Roger A Barker" Clear advanced filters

  • A recent article published in Brain proposes a clinical method for subtyping Parkinson disease cases on an individual basis, with implications for better patient stratification for personalized medicine. The authors report biological validity in terms of imaging and cerebrospinal fluid parameters, but long-term predictive validity remains to be established.

    • Caroline H. Williams-Gray
    • Roger A. Barker
    News & Views
    Nature Reviews Neurology
    Volume: 13, P: 454-455

  • One of the main challenges associated with late-onset genetic neurodegenerative diseases is predicting when the condition begins and how it progresses over time. In a new study, Tabrizi et al. have used a range of imaging, clinical and neuropsychiatric measures to assess the progression of Huntington disease.

    • Roger A. Barker
    • Sarah L. Mason
    News & Views
    Nature Reviews Neurology
    Volume: 7, P: 192-193

  • A key challenge to improving the design of clinical trials in Huntington disease (HD) has been the limited data on the natural history of HD. A recent prospective longitudinal study has provided important information in this regard, which could be useful for future translation of disease-modifying therapies for early-stage HD.

    • Roger A. Barker
    • Sarah L. Mason
    News & Views
    Nature Reviews Neurology
    Volume: 10, P: 12-13

  • Following the success of pharmacological dopamine replacement in patients with Parkinson disease (PD), cell-based dopamine replacement strategies seemed the next logical step. In this Review, the authors outline the history of this therapeutic approach to PD, emphasizing the importance of obtaining robust preclinical data before proceeding to clinical trials. In addition, they discuss the challenges of bringing the new generation of stem cell-derived dopamine cells to the clinic.

    • Roger A. Barker
    • Janelle Drouin-Ouellet
    • Malin Parmar
    Reviews
    Nature Reviews Neurology
    Volume: 11, P: 492-503

  • Disruption of circadian rhythms in neurodegenerative disorders not only contributes to morbidity and poor quality of life, but could also be involved in driving the disease process itself. Restoration of circadian rhythmicity via behavioural or pharmacological interventions might, therefore, slow down disease progression. In this Review, Videnovic and colleagues provide an overview of the circadian system, and summarize current understanding of the dysfunction of circadian rhythms in Alzheimer disease, Parkinson disease and Huntington disease.

    • Aleksandar Videnovic
    • Alpar S. Lazar
    • Sebastiaan Overeem
    Reviews
    Nature Reviews Neurology
    Volume: 10, P: 683-693